Comparison of BSAC agar dilution and NCCLS broth microdilution MIC methods for in vitro susceptibility testing of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: The BSAC Respiratory Resistance Surveillance Programme

Rosy Reynolds; Jemma Shackcloth; David Felmingham; Alasdair P. MacGowan; J. Booth; D. F.J. Brown; S. Coles; I. Harding; D. M. Livermore; V. Reed; D. Lofland; C. Thomson; A. White; R. Wise; M. Robbins

doi:10.1093/jac/dkg462

Comparison of BSAC agar dilution and NCCLS broth microdilution MIC methods for in vitro susceptibility testing of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: The BSAC Respiratory Resistance Surveillance Programme

Rosy Reynolds^*, Jemma Shackcloth, David Felmingham, Alasdair P. MacGowan, J. Booth, D. F.J. Brown, S. Coles, I. Harding, D. M. Livermore, V. Reed, D. Lofland, C. Thomson, A. White, R. Wise, M. Robbins

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

28 Citations (Scopus)

Abstract

Objective: The aim of this study was to establish the degree of comparability between the NCCLS broth microdilution and BSAC agar dilution MIC methods of antimicrobial susceptibility testing. Methods: Six hundred and sixty-one clinical isolates of Streptococcus pneumoniae, 936 Haemophilus influenzae and 421 Moraxella catarrhalis, collected in the winter of 1999-2000 by 20 laboratories in the UK and Eire from patients with presumed community-acquired lower respiratory infections, were tested by the two methods. MIC agreement was defined as excellent (good) if results were within ±1 doubling dilution for ≥90% (≥80%) of isolates and within ±2 doubling dilutions for ≥95%. Isolates were categorized as susceptible, intermediate or resistant using the breakpoints appropriate to the testing method. Results: MIC agreement was good or excellent in 27 of 36 organism-agent combinations. Agreement was less for M. catarrhalis than for other species, and lower in all three species for cefaclor and trimethoprim than for other antimicrobials. Discrepancies in categorization occurred only occasionally, and were generally explained by differences in breakpoints rather than in measured MICs. One exception was S. pneumoniae with penicillin. Despite excellent MIC agreement and identical breakpoints, 9% of these had minor discrepancies, mainly because 7% of isolates were found intermediate by the BSAC method but resistant by the NCCLS method. Conclusion: There is generally very good agreement between the MICs obtained by the BSAC agar dilution and NCCLS broth microdilution methods in this population of isolates, comparable to the level of agreement achieved between different laboratories using a single method. Breakpoint differences contribute to most of the discrepancies in susceptibility categorization.

Original language	English
Pages (from-to)	925-930
Number of pages	6
Journal	Journal of Antimicrobial Chemotherapy
Volume	52
Issue number	6
DOIs	https://doi.org/10.1093/jac/dkg462
Publication status	Published - Dec 2003

Bibliographical note

Funding Information:
Members of the Working Party and Contributors: Working Party Members, June 2003: A. P. MacGowan (Chair) (Department of Medical Microbiology, North Bristol NHS Trust), J. Booth (Bayer Pharmaceuticals, Slough), D. F. J. Brown (Addenbrookes Hospital, Cambridge), S. Coles (Abbott Laboratories Ltd, Maidenhead), D. Felmingham (GR Micro Ltd, London), I. Harding (Micron Research Limited, Wisbech), D. M. Livermore (Health Protection Agency, London), V. Reed (Micron Research Limited, Wisbech), R. A. Reynolds (Department of Medical Microbiology, North Bristol NHS Trust), J. Shackcloth (GR Micro Ltd, London), D. Lofland (GeneSoft Pharmaceuticals, San Francisco, CA, USA), C. Thomson (Bayer Pharmaceuticals, Slough), A. White (GlaxoSmithKline, Harlow) and R. Wise (City Hospital, Birmingham); scientific services management: M. Robbins (GR Micro Ltd, London). Supporters and sponsors: the BSAC Respiratory Resistance Surveillance Programme 1999/2001 was supported by the British Society for Antimicrobial Chemotherapy and sponsored by Abbott Laboratories Ltd, Aventis Pharma Ltd, Bayer Pharmaceuticals and Glaxo-SmithKline.

Keywords

Antimicrobial susceptibility
Methodology
Respiratory pathogens

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jac/dkg462

Fingerprint

Dive into the research topics of 'Comparison of BSAC agar dilution and NCCLS broth microdilution MIC methods for in vitro susceptibility testing of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: The BSAC Respiratory Resistance Surveillance Programme'. Together they form a unique fingerprint.

Cite this

Reynolds, R., Shackcloth, J., Felmingham, D., MacGowan, A. P., Booth, J., Brown, D. F. J., Coles, S., Harding, I., Livermore, D. M., Reed, V., Lofland, D., Thomson, C., White, A., Wise, R., & Robbins, M. (2003). Comparison of BSAC agar dilution and NCCLS broth microdilution MIC methods for in vitro susceptibility testing of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: The BSAC Respiratory Resistance Surveillance Programme. Journal of Antimicrobial Chemotherapy, 52(6), 925-930. https://doi.org/10.1093/jac/dkg462

Reynolds, Rosy ; Shackcloth, Jemma ; Felmingham, David et al. / Comparison of BSAC agar dilution and NCCLS broth microdilution MIC methods for in vitro susceptibility testing of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis : The BSAC Respiratory Resistance Surveillance Programme. In: Journal of Antimicrobial Chemotherapy. 2003 ; Vol. 52, No. 6. pp. 925-930.

@article{f9c291022efb426396b07d12fc163c78,

title = "Comparison of BSAC agar dilution and NCCLS broth microdilution MIC methods for in vitro susceptibility testing of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: The BSAC Respiratory Resistance Surveillance Programme",

abstract = "Objective: The aim of this study was to establish the degree of comparability between the NCCLS broth microdilution and BSAC agar dilution MIC methods of antimicrobial susceptibility testing. Methods: Six hundred and sixty-one clinical isolates of Streptococcus pneumoniae, 936 Haemophilus influenzae and 421 Moraxella catarrhalis, collected in the winter of 1999-2000 by 20 laboratories in the UK and Eire from patients with presumed community-acquired lower respiratory infections, were tested by the two methods. MIC agreement was defined as excellent (good) if results were within ±1 doubling dilution for ≥90% (≥80%) of isolates and within ±2 doubling dilutions for ≥95%. Isolates were categorized as susceptible, intermediate or resistant using the breakpoints appropriate to the testing method. Results: MIC agreement was good or excellent in 27 of 36 organism-agent combinations. Agreement was less for M. catarrhalis than for other species, and lower in all three species for cefaclor and trimethoprim than for other antimicrobials. Discrepancies in categorization occurred only occasionally, and were generally explained by differences in breakpoints rather than in measured MICs. One exception was S. pneumoniae with penicillin. Despite excellent MIC agreement and identical breakpoints, 9% of these had minor discrepancies, mainly because 7% of isolates were found intermediate by the BSAC method but resistant by the NCCLS method. Conclusion: There is generally very good agreement between the MICs obtained by the BSAC agar dilution and NCCLS broth microdilution methods in this population of isolates, comparable to the level of agreement achieved between different laboratories using a single method. Breakpoint differences contribute to most of the discrepancies in susceptibility categorization.",

keywords = "Antimicrobial susceptibility, Methodology, Respiratory pathogens",

author = "Rosy Reynolds and Jemma Shackcloth and David Felmingham and MacGowan, {Alasdair P.} and J. Booth and Brown, {D. F.J.} and S. Coles and I. Harding and Livermore, {D. M.} and V. Reed and D. Lofland and C. Thomson and A. White and R. Wise and M. Robbins",

note = "Funding Information: Members of the Working Party and Contributors: Working Party Members, June 2003: A. P. MacGowan (Chair) (Department of Medical Microbiology, North Bristol NHS Trust), J. Booth (Bayer Pharmaceuticals, Slough), D. F. J. Brown (Addenbrookes Hospital, Cambridge), S. Coles (Abbott Laboratories Ltd, Maidenhead), D. Felmingham (GR Micro Ltd, London), I. Harding (Micron Research Limited, Wisbech), D. M. Livermore (Health Protection Agency, London), V. Reed (Micron Research Limited, Wisbech), R. A. Reynolds (Department of Medical Microbiology, North Bristol NHS Trust), J. Shackcloth (GR Micro Ltd, London), D. Lofland (GeneSoft Pharmaceuticals, San Francisco, CA, USA), C. Thomson (Bayer Pharmaceuticals, Slough), A. White (GlaxoSmithKline, Harlow) and R. Wise (City Hospital, Birmingham); scientific services management: M. Robbins (GR Micro Ltd, London). Supporters and sponsors: the BSAC Respiratory Resistance Surveillance Programme 1999/2001 was supported by the British Society for Antimicrobial Chemotherapy and sponsored by Abbott Laboratories Ltd, Aventis Pharma Ltd, Bayer Pharmaceuticals and Glaxo-SmithKline.",

year = "2003",

month = dec,

doi = "10.1093/jac/dkg462",

language = "English",

volume = "52",

pages = "925--930",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "6",

}

Reynolds, R, Shackcloth, J, Felmingham, D, MacGowan, AP, Booth, J, Brown, DFJ, Coles, S, Harding, I, Livermore, DM, Reed, V, Lofland, D, Thomson, C, White, A, Wise, R & Robbins, M 2003, 'Comparison of BSAC agar dilution and NCCLS broth microdilution MIC methods for in vitro susceptibility testing of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: The BSAC Respiratory Resistance Surveillance Programme', Journal of Antimicrobial Chemotherapy, vol. 52, no. 6, pp. 925-930. https://doi.org/10.1093/jac/dkg462

Comparison of BSAC agar dilution and NCCLS broth microdilution MIC methods for in vitro susceptibility testing of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: The BSAC Respiratory Resistance Surveillance Programme. / Reynolds, Rosy; Shackcloth, Jemma; Felmingham, David et al.
In: Journal of Antimicrobial Chemotherapy, Vol. 52, No. 6, 12.2003, p. 925-930.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Comparison of BSAC agar dilution and NCCLS broth microdilution MIC methods for in vitro susceptibility testing of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis

T2 - The BSAC Respiratory Resistance Surveillance Programme

AU - Reynolds, Rosy

AU - Shackcloth, Jemma

AU - Felmingham, David

AU - MacGowan, Alasdair P.

AU - Booth, J.

AU - Brown, D. F.J.

AU - Coles, S.

AU - Harding, I.

AU - Livermore, D. M.

AU - Reed, V.

AU - Lofland, D.

AU - Thomson, C.

AU - White, A.

AU - Wise, R.

AU - Robbins, M.

N1 - Funding Information: Members of the Working Party and Contributors: Working Party Members, June 2003: A. P. MacGowan (Chair) (Department of Medical Microbiology, North Bristol NHS Trust), J. Booth (Bayer Pharmaceuticals, Slough), D. F. J. Brown (Addenbrookes Hospital, Cambridge), S. Coles (Abbott Laboratories Ltd, Maidenhead), D. Felmingham (GR Micro Ltd, London), I. Harding (Micron Research Limited, Wisbech), D. M. Livermore (Health Protection Agency, London), V. Reed (Micron Research Limited, Wisbech), R. A. Reynolds (Department of Medical Microbiology, North Bristol NHS Trust), J. Shackcloth (GR Micro Ltd, London), D. Lofland (GeneSoft Pharmaceuticals, San Francisco, CA, USA), C. Thomson (Bayer Pharmaceuticals, Slough), A. White (GlaxoSmithKline, Harlow) and R. Wise (City Hospital, Birmingham); scientific services management: M. Robbins (GR Micro Ltd, London). Supporters and sponsors: the BSAC Respiratory Resistance Surveillance Programme 1999/2001 was supported by the British Society for Antimicrobial Chemotherapy and sponsored by Abbott Laboratories Ltd, Aventis Pharma Ltd, Bayer Pharmaceuticals and Glaxo-SmithKline.

PY - 2003/12

Y1 - 2003/12

N2 - Objective: The aim of this study was to establish the degree of comparability between the NCCLS broth microdilution and BSAC agar dilution MIC methods of antimicrobial susceptibility testing. Methods: Six hundred and sixty-one clinical isolates of Streptococcus pneumoniae, 936 Haemophilus influenzae and 421 Moraxella catarrhalis, collected in the winter of 1999-2000 by 20 laboratories in the UK and Eire from patients with presumed community-acquired lower respiratory infections, were tested by the two methods. MIC agreement was defined as excellent (good) if results were within ±1 doubling dilution for ≥90% (≥80%) of isolates and within ±2 doubling dilutions for ≥95%. Isolates were categorized as susceptible, intermediate or resistant using the breakpoints appropriate to the testing method. Results: MIC agreement was good or excellent in 27 of 36 organism-agent combinations. Agreement was less for M. catarrhalis than for other species, and lower in all three species for cefaclor and trimethoprim than for other antimicrobials. Discrepancies in categorization occurred only occasionally, and were generally explained by differences in breakpoints rather than in measured MICs. One exception was S. pneumoniae with penicillin. Despite excellent MIC agreement and identical breakpoints, 9% of these had minor discrepancies, mainly because 7% of isolates were found intermediate by the BSAC method but resistant by the NCCLS method. Conclusion: There is generally very good agreement between the MICs obtained by the BSAC agar dilution and NCCLS broth microdilution methods in this population of isolates, comparable to the level of agreement achieved between different laboratories using a single method. Breakpoint differences contribute to most of the discrepancies in susceptibility categorization.

AB - Objective: The aim of this study was to establish the degree of comparability between the NCCLS broth microdilution and BSAC agar dilution MIC methods of antimicrobial susceptibility testing. Methods: Six hundred and sixty-one clinical isolates of Streptococcus pneumoniae, 936 Haemophilus influenzae and 421 Moraxella catarrhalis, collected in the winter of 1999-2000 by 20 laboratories in the UK and Eire from patients with presumed community-acquired lower respiratory infections, were tested by the two methods. MIC agreement was defined as excellent (good) if results were within ±1 doubling dilution for ≥90% (≥80%) of isolates and within ±2 doubling dilutions for ≥95%. Isolates were categorized as susceptible, intermediate or resistant using the breakpoints appropriate to the testing method. Results: MIC agreement was good or excellent in 27 of 36 organism-agent combinations. Agreement was less for M. catarrhalis than for other species, and lower in all three species for cefaclor and trimethoprim than for other antimicrobials. Discrepancies in categorization occurred only occasionally, and were generally explained by differences in breakpoints rather than in measured MICs. One exception was S. pneumoniae with penicillin. Despite excellent MIC agreement and identical breakpoints, 9% of these had minor discrepancies, mainly because 7% of isolates were found intermediate by the BSAC method but resistant by the NCCLS method. Conclusion: There is generally very good agreement between the MICs obtained by the BSAC agar dilution and NCCLS broth microdilution methods in this population of isolates, comparable to the level of agreement achieved between different laboratories using a single method. Breakpoint differences contribute to most of the discrepancies in susceptibility categorization.

KW - Antimicrobial susceptibility

KW - Methodology

KW - Respiratory pathogens

UR - http://www.scopus.com/inward/record.url?scp=10744233107&partnerID=8YFLogxK

U2 - 10.1093/jac/dkg462

DO - 10.1093/jac/dkg462

M3 - Article

C2 - 14585864

AN - SCOPUS:10744233107

SN - 0305-7453

VL - 52

SP - 925

EP - 930

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 6

ER -

Reynolds R, Shackcloth J, Felmingham D, MacGowan AP, Booth J, Brown DFJ et al. Comparison of BSAC agar dilution and NCCLS broth microdilution MIC methods for in vitro susceptibility testing of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: The BSAC Respiratory Resistance Surveillance Programme. Journal of Antimicrobial Chemotherapy. 2003 Dec;52(6):925-930. doi: 10.1093/jac/dkg462

Comparison of BSAC agar dilution and NCCLS broth microdilution MIC methods for in vitro susceptibility testing of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: The BSAC Respiratory Resistance Surveillance Programme

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this